Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.

Despite an FDA request to halt shipments, Sarepta Therapeutics (NASDAQ:SRPT) announced late Friday that the company will ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

(NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating ...

Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...

Here are Investing.com’s stocks of the week. CRCL rallied, with the stock boosted by news that the U.S. House of ...

A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...

Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.

Sarepta Therapeutics announces layoffs of 493 employees, including 80 in Franklin County, amid restructuring efforts and ...

The FDA asked Sarepta Therapeutics to halt shipments of its Elevidys gene therapy after a patient's death linked to a similar treatment. Sarepta will continue shipments for ambulatory patients but ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...